ArticleBMC medical imaging2026
Multicenter prospective study of dedicated breast positron emission tomography (dbPET) for breast cancer: examination in preoperative patients.
Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDedicated breast positron emission tomography (dbPET) was developed to detect breast cancers smaller than those detectable using whole-body PET (wbPET). Although several studies have explored the use of dbPET, clear criteria for identifying which patients would benefit most from this modality are lacking. Our objective was to determine which patient groups would benefit most from dbPET and how it should be utilized. We conducted a multicenter, prospective exploratory study to investigate how the dbPET maximum standardized uptake values (SUVmax) correlate with patients' clinical characteristics, other imaging modalities, and pathological findings of the lesions.
methodsIn total, 219 patients with breast cancer (median age [range], 58.0 [30-83] years) were included in this study. The enrolled patients were divided into three groups (primary care, neoadjuvant therapy, postoperative follow-up patients). In this research, we examined the primary care group (n = 92). To investigate which patient groups benefit from dbPET, we examined which factors influence and correlate with dbPET SUVmax. Depending on the items being compared, correlation analysis, Wilcoxon signed rank test was used to examine the following items. Which factors (physical factors, pathological characteristics, etc.) correlate with dbPET SUVmax, differences between dbPET and other imaging examination (detection rate, etc.), and whether dbPET SUVmax L/H ratio (Lesion-to-Healthy (normal) site dbPET SUVmax ratio) incorporating dbPET SUVmax from healthy (normal) mammary gland tissue are necessary for evaluating dbPET SUVmax in lesion areas.
resultsdbPET SUVmax in healthy(normal) mammary gland tissue were strongly associated with background mammary density observed on mammography (MMG) examination (positive correlation, p<0.05). Ki-67 showed the strongest positive correlation with both the lesion-site dbPET SUVmax (r=0.56, R
conclusionsdbPET demonstrated higher detection capabilities than other imaging tests and showed a strong correlation with tissue malignancy. Therefore, they were suggested to be potentially useful for distinguishing benign findings from malignant lesions that are difficult to differentiate using other imaging tests. The dbPET SUVmax of healthy mammary gland tissue were presumed to correlate with the amount of mammary gland tissue within the breast. However, no significant differences were observed in the correlations between the dbPET values and the L/H ratio and the individual parameters. In this study, it remained unclear whether the dbPET values of normal breast tissue should be taken into account when evaluating dbPET values.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.